Clinical Trial Detail

NCT ID NCT04209621
Title Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Duvelisib + Ibrutinib

Age Groups:

No variant requirements are available.